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Abstract
Introduction: α-Smooth muscle actin (α-SMA)-positive hepatic stellate cells
(HSCs) are pericytes responsible for fibrosis in chronic liver injury. The glial
fibrillary acidic protein (GFAP), commonly expressed by astrocytes in the central
nervous system, is expressed in vivo in the liver in a subpopulation of quiescent
stellate cells. The reports concerning GFAP expression in human liver are still
conflicting. The aim of the study is investigation the utility of GFAP compared
to α-SMA as an indicator of early activated HSCs, in predicting fibrosis in chronic
hepatitis C (CHC) patients.
Material and methods: With immunohistochemistry and a semi-quantitative
scoring system, the expressions of α-SMA and GFAP on HSCs in liver biopsies
from patients with pure CHC (n = 34), hepatitis C virus-induced cirrhosis 
(n = 24), mixed CHC/schistosomiasis (n = 11) and normal controls (n = 10) were
analysed. 
Results: The immunoreactivity of α-SMA and GFAP in perisinusoidal, periportal
and pericentral areas was assessed. α-Smooth muscle actin and GFAP-positive
HSCs were significantly increased in all diseased groups compared with normal
controls. In pure CHC with or without cirrhosis, perisinusoidal α-SMA-positive
HSCs were predominant in relation to GFAP-positive cells. On the other hand,
GFAP-positive cells were predominant in the group of schistosomiasis as
compared with the other diseased groups. It was noticed that expression of
GFAP on perisinusoidal HSCs in CHC patients sequentially decreased with the
progression of fibrosis.
Conclusions: Glial fibrillary acidic protein could represent a more useful marker
than α-SMA of early activation of HSCs in CHC patients and seems to be an
early indicator of hepatic fibrogenesis.
Key words: α-smooth muscle actin, glial fibrillary acidic protein, chronic hepatitis C,
fibrosis, stellate cell.
Introduction 
Hepatitis C virus (HCV) infection affects more than 170 million people
worldwide, with the great majority (~85%) of patients developing chronic
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HCV infection [1]. Chronic hepatitis C (CHC) is
considered the most common chronic liver disease
(CLD) in Egypt, where prevalence of antibodies to
HCV (anti-HCV) is approximately 10-fold greater
than in the United States and Europe [2]. 
The main injury caused by HCV is hepatic
fibrosis, as a result of a chronic inflammatory
process in the liver. The development of CHC is
better estimated by the fibrosis stage rather than
by the necroinflammatory activity level [3].
Currently, the cirrhosis resulting from chronic 
virus C infection is the main cause of hepatic
transplantation worldwide [4]. 
Schistosoma mansoni infects tens of millions 
of people in many developing countries [5]. In
contrast to CHC infection, which causes severe
necroinflammatory lesions and diffuse parenchymal
damage, the schistosomal granulomatous inflam  -
mation is restricted to the periportal zone, 
does not induce hepatocellular degeneration or
necrosis, and preserves hepatic lobular architecture
and function [6].
Hepatic stellate cells (HSCs) exist in the space
between parenchymal cells and sinusoidal
endothelial cells of the hepatic lobule and store
80% of retinoids in the whole body. In pathological
conditions such as liver fibrosis, HSCs lose retinoids,
and synthesize a large amount of extracellular
matrix (ECM) components. Morphology of these
cells also changes from the star-shaped stellate cells
to that of fibroblasts or myofibroblasts [7]. Indeed,
the paradigm of stellate cell activation into
contractile myofibroblasts as the major pathway in
hepatic fibrogenesis associated with liver injury has
dominated the focus of studies on this fascinating
cell type [8]. In response to liver injury, human HSCs
express α-smooth muscle actin (α-SMA), becoming
"activated" and myofibroblast-like [9]. The cor  -
relation between HSC activation and necro  -
inflammatory activity and/or fibrosis stage is a point
of much debate [10].
Glial fibrillary acidic protein (GFAP) is an
intermediate filament protein that is found in glial
cells [11]. Few studies have been performed in order
to quantify the hepatic expression of GFAP at
different stages of human chronic hepatitis [12]. The
predominance of GFAP-positive cells observed in
schistosomiasis suggests that HSCs have a major
role in connective tissue deposition in the human
schistosomal liver [13].
Hence, finding precocious markers of activated
HSCs will be helpful in identifying early stages of
hepatic fibrosis when the antiviral therapy is
expected to reduce fibrosis progression. So, the
aims of this work were: to correlate α-SMA and/or
GFAP-positive HSCs with the severity of liver injury
in the context of degree of necroinflammatory
activity and stage of fibrosis in HCV infected
patients, and to investigate the value of these
markers as indicators of hepatic stellate cell
activation, in predicting early fibrosis in CHC.
Material and methods
This prospective study was conducted on 69
patients with CLD admitted to the Department of
Hepato-Gastroenterology, Theodor Bilharz Research
Institute, Egypt in the period of 2004-2007. Fifty-eight
were males (84.1%) and 11 were females (15.9%).
Their ages ranged from 20 to 57 years with a mean
of 40.82 ±8.98. All had circulating anti-HCV antibodies
or HCV-RNA viraemia with no serological evidence of
co-infection with hepatitis B virus. Patients with
a history of antiviral therapy were excluded from the
study. All patients were subjected to thorough clinical
examination, routine laboratory investigations,
abdominal ultrasound (Hitachi EuB-515A), rectal snip
examination for detection of Schistosoma ova and
upper endoscopy whenever indicated. Core liver
biopsies were performed for all patients with safety
precautions to minimize any consequent risk using
a percutaneous ultrasound-guided Menghini needle
for histopathological and immunohistochemical
studies. The control group included 10 wedge liver
biopsies taken during laparoscopic cholecystectomy
from age- and sex-matched healthy subjects. They
all had clinical, biochemical, serological, ultra  -
sonographic and histological findings within the
normal range. They were 8 males and 2 females.
Their ages ranged between 26 and 52 years with
a mean of 40.0 ±8.72 years. Our study followed the
tenets of the Declaration of Helsinki [14]. 
Laboratory investigations
– Complete blood picture.
– Prothrombin time and concentration.
– Liver function tests including albumin, aspartate
aminotransferase (AST), alanine aminotransferase
(ALT) and alkaline phosphatase (ALP). 
– Hepatitis viral markers including hepatitis B
surface antigen, anti-HBs antibodies, and total
and IgM class antibodies against hepatitis B core
antigen using enzyme immunoassay kits (Murex
Diagnostics, Dartford, England). Anti-HCV
antibodies using version V anti-HCV ELISA kit
(Murex Diagnostics, Dartford, England). Cir  -
culating HCV-RNA was assayed to confirm the
presence of HCV antigenaemia by nested RT-PCR
using a set of primers within the 5' non-translated
region according to Saber et al. [15]. 
– Anti-nuclear antibodies (ANA) using ELISA kit
(Quanta LiteTM ANA, Inova Diagnostics. Inc., USA)
to exclude autoimmune hepatitis.
Histopathological studies
Serial sections (5-µm thick) from formalin-fixed,
paraffin-embedded core liver biopsies were stained
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with haematoxylin and eosin for routine histo  -
pathological examination. Masson trichrome stain
was used for proper demonstration of fibrous tissue
deposition. Liver sections with evidence of HCV
infection were graded according to the degree of
periportal and intralobular inflammation, interface
hepatitis and portal inflammation. The grades of CHC
activity (scale A0-A3) and the stage of fibrosis (scale
F0-F4) were assessed according to the METAVIR
scoring system [16]. Grade 1 inflammation as well as
the first and second stages of fibrosis were considered
as a "low score", while grades 2 and 3 inflammation
as well as the third and fourth stages of fibrosis were
considered as a "high score". According to the above-
mentioned clinical, serological and histopathological
criteria, subjects included in this study were
categorized into the following groups: (a) control 
(n = 10), (b) pure CHC with no cirrhosis or
schistosomiasis (n = 34), (c) HCV-induced liver
cirrhosis (LC) (n = 14) and (d) mixed lesion of CHC
with schistosomiasis (n = 11).
Immunohistochemical technique
Five-µm thick sections from formalin-fixed,
paraffin-embedded liver tissue from all cases were
cut on microscopic slides coated with 3-amino
propyl triethoxysilane (Sigma Chemicals; St. Louis,
Missouri) for proper fixation of tissue sections on
the slides and to minimize staining artefacts. 
After deparaffinization and subsequent blockage
of the endogenous peroxidase activity by
incubation in 0.3% methanolic hydrogen peroxide
(10 min), the sections were then washed in
phosphate buffered saline (PBS). Antigen retrieval
was performed by boiling the slides twice in 
10 mmol/l citrate buffer solution (pH 6.0) (DAKO,
Denmark) each for 5 min. Tissue sections were
treated with normal horse serum (Dako, Denmark)
for 10 min to avoid non-specific immunoreactivity.
Duplicate liver sections were incubated overnight
at 4°C with mouse monoclonal anti-α-SMA antibody
(DAKO, clone 1A4) diluted 1 : 50 and ready-to-use
mouse monoclonal anti-GFAP antibody (BioGenex,
USA). Sections were then incubated at room
temperature with biotinylated goat anti-mouse
antibody for 10 min followed by streptavidin
horseradish peroxidase conjugate (all from Dako,
Denmark). The reaction was visualized by the
addition of diaminobenzidine substrate solution
(Dako, Denmark) followed by counterstaining with
Mayer’s haematoxylin. Positive and negative control
slides were included within each session. 
The immunoexpression of both α-SMA and GFAP
on HSCs was scored for perisinusoidal, periportal
and pericentral areas. Parenchymal HSCs were
characterized by morphological criteria (perisi  -
nusoidally located, stellate-shaped cells residing in
the parenchymal lobules or nodules) [12]. The
number of positive and negative perisinusoidal HSCs
was separately counted for each of α-SMA and GFAP
under a light microscope at 200× magnification. For
each slide, positive HSCs were counted in at least
7-10 microscopic fields of maximum staining
intensity. The percentage of positive HSCs was
calculated based on the total number of HSCs
counted in each slide. The average percentage of
positive HSCs was then calculated for each group
[17]. The scores for periportal and pericentral areas
were determined semi-quantitatively as 0: no
staining or < 3% of the region; 1) positive for 3-33%
of the region, 2) positive for 34-66% of the region,
and 3) positive for > 66% of the region [18].
Statistical analysis 
Results are presented as the mean ± standard
deviation. Statistical procedures were performed using
SPSS statistical software (version 16, Chicago, III).
Comparisons between multiple groups were carried
out using one-way ANOVA and between two groups
by Scheffé’s test. Where indicated, Pearson's
correlation coefficient was used. Probability values
less than 0.05 were considered to be statistically
significant.
Results
Sixty-nine patients suffering from chronic HCV
infection were enrolled in this study. Past history of
schistosomiasis was recorded in 11/69 (15.94%) 
of the studied patients and proved by rectal 
snip examination. The clinical and abdominal
ultrasonographic features of the studied HCV
patients are shown in Table I. While the majority of
the patients (87%) presented with fatigue, none of
them had clinically detected jaundice or ascites.
Ultrasonographic examination revealed that none
of the patients had a shrunken liver. As regards the
sonographic texture of the liver, a coarse pattern
was detected in 43.5%; however, a mixed bilharzial
and bright pattern was detected in only 4.3% of the
studied patients. 
Immunohistochemical studies
The total number of HSCs immunostained by 
α-SMA and GFAP in each group was semi-
quantitatively assessed in perisinusoidal, periportal
and pericentral areas of the hepatic lobules. Hepatic
stellate cells were observed to be variable in size
and shape, although most of them were found
stretched with long cytoplasmic processes along
the endothelial lining.
Immunoexpression of α-smooth muscle actin
on hepatic stellate cells
In the control group, very few α-SMA-positive
HSCs were detected only along the sinusoids 
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(Figure 1A) with a significant difference from the
other groups (p < 0.01). In pure CHC patients, 
α-SMA-positive cells were mainly located peri  -
sinusoidally and were more strongly and diffusely
immunostained (Figure 1B). In the cirrhotic group,
α-SMA-positive HSCs were observed in the 
inter-parenchymal expanding septae as well as in
the perisinusoidal spaces of the residual hepatic
parenchyma, while in areas demonstrating
regenerative activity, positive HSCs were confined
to the periphery of the regenerative plates 
(Figure 1C).
The highest value of perisinusoidal α-SMA-
positive cells was encountered in pure CHC cases,
with a significant difference compared with those
mixed with schistosomiasis and controls (p < 0.01).
However, the highest score of periportal and
pericentral positive cells was detected in liver
cirrhosis, with a significant difference from the
other studied groups (Table II).
Concerning the grades of necroinflammatory
activity and stages of fibrosis in CHC, patients with
low grade (A0-A1) showed a significantly higher 
α-SMA immunoexpression on perisinusoidal HSCs
when compared with those of higher grades 
(A2-A3) (p < 0.01). It was found that α-SMA-positive
HSCs were detectable in all stages of hepatic
fibrosis. In cases of CHC with no evidence of fibrosis
(F0), the mean value of perisinusoidal expression
of α-SMA-positive HSCs was 21.25 ±7.84. However,
the expression was completely absent in the
periportal area, with a slightly higher value in the
Characteristics Patients (n = 69)
Symptoms:
– Fatigue 60 (87%)
– Rt. hypochondrial dull aching pain 45 (65.2%)
Signs:
– Hepatomegaly 7 (10.15%)
– Splenomegaly 0 (0%)
Liver:
• Size:
– Average 55 (79.7%)
– Enlarged 14 (20.3%)
– Shrunken 0 (0%)
• Texture:
– Normal 15 (21.7%)
– Bright 21 (30.4%)
– Coarse 30 (43.5%)
– Mixed bilharzial and bright pattern 3 (4.3%)
Spleen:
• Enlarged 10 (14.5%)
Portal vein dilatation 0 (0%)
Table I. Clinical and abdominal ultrasonographic
characteristics of the studied HCV patients
A
B
C
Figure 1. A – Control liver section showing very few
perisinusoidal α-SMA-positive HSCs (Immunohisto  -
chemistry ×400). B – Periportal and perisinusoidal 
α-SMA-positive HSCs in a liver section with CHC of
low grade and stage (METAVIR score: A1F1) (Immuno  -
histochemistry ×200). C – Remarkable increase of 
α-SMA-positive HSCs in a liver section with active
cirrhosis. Many HSCs are visible in expanding fibrous
setae with few positive cells seen within the
perisinusoidal spaces of the upper hepatic nodule
(immunohistochemistry ×400)
α-SMA – α-smooth muscle actin, HSCs – hepatic
stellate cells 
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pericentral zone (0.63 ±0.49). In LC (F3-F4),
perisinusoidal positivity was significantly decreased
compared to the low stage (p < 0.01) and this
relation was inverted in periportal and pericentral
areas (Table III).
Immunoexpression of glial fibrillary acidic
protein on hepatic stellate cells
The control liver sections showed almost GFAP-
negative HSCs with sporadic perisinusoidally
positive cells found in the hepatic parenchyma
(Figure 2A), with a significant difference vs. the
other diseased groups (p < 0.01). In the CHC group,
GFAP-positive HSCs were more evenly distributed
throughout the hepatic lobule. However, in the
cirrhotic group, GFAP-positive cells were not
strongly and diffusely immunostained.
As patients with pure CHC showed a paucity of
periportal and pericentral GFAP-positive HSCs, with
a significant difference to the other diseased groups
(p < 0.01), those mixed with schistosomiasis had
the highest value of GFAP expression in the three
zones (Table IV, Figure 2B). It was found that in 
low grade necroinflammatory activity (A0-A1),
a significantly higher expression of GFAP-positive
HSCs was detected in the perisinusoidal zone when
compared with higher grades of activity (A2-A3) 
(p < 0.01). For stage F0, the expression of GFAP on
perisinusoidal HSCs was the highest (24.38 ±5.77),
with a significant difference vs. controls and
patients with higher scores (p < 0.01) (Figures 2C,
2D). In contrast, patients with LC (F3-F4) showed
the lowest value of GFAP expression on peri  -
sinusoidal HSCs (9.83 ±5.01) and the highest value
for periportal and pericentral HSCs, with
a significant difference vs. the other cases with
lower stages of fibrosis (Table V). 
In CHC with or without LC, perisinusoidal α-SMA-
positive HSCs were highly predominant in relation
to GFAP-positive cells. Interestingly, the number of
GFAP-positive cells was not only smaller in the
former biopsies but the ratio to the α-SMA-positive
cells was also inverted compared to those with
mixed schistosomiasis (Figure 3).
Among the studied HCV-infected patients, there
was no significant correlation between the
expression of both markers and the clinico-
laboratory variables of those patients, grades of
necroinflammatory activity and stages of fibrosis.
On the other hand, there was a significant
correlation between the expression of both α-SMA
and GFAP in liver biopsies of the studied HCV
patients (r = 0.313, p < 0.01) (Figure 4).
Discussion 
Hepatic fibrosis is a major feature of the liver
injury that accompanies chronic HCV infection and
in many patients leads to cirrhosis and end-stage
liver disease. HSC activation, occurring in response
to tissue injury and oxidative stress, is believed to
be the central event in fibrosis [19]. However, the
exact molecular events leading to HSC activation
are not well understood. It is believed that stellate
cells proliferate as a response to inflammation and
secrete growth factors, cytokines, type I and type IV
collagen, laminin and heparin sulphate. These cells
Groups Perisinusoidal*, mean ± SD Periportal#, mean ± SD Pericentral#, mean ± SD
Control (n = 10) 3.5 ±1.65  0 0
Pure chronic hepatitis C (n = 34)  22.00 ±13.98a 0.70 ±0.48  1.10 ±0.32 
Liver cirrhosis (n = 24) 16.5 ±7.41a 2.63 ±0.49a,b 2.63 ±0.49a,b
Mixed CHC/schistosomiasis (n = 11)  9.64 ±5.26b,c 1.82 ±0.75a,b,d 1.73 ±0.79a,b,d
Table II. Immunoexpression of α-SMA on HSCs in the studied groups
*percentage of positive cells/group, #semi-quantitative scoring of positive cells/group, ap < 0.01 vs. control, bp < 0.01 vs. pure CHC (chronic hepatitis C),
cp < 0.05, dp < 0.01 vs. liver cirrhosis
Table III. Immunoexpression of α-SMA on HSCs in controls and HCV patients with different grades and stages
Groups Perisinusoidal*, mean ± SD Periportal#, mean ± SD Pericentral#, mean ± SD
Control (n = 10)  3.5 ±1.65  0 0
Chronic hepatitis C (n = 69)  21.64 ±12.0a 1.48 ±0.98 1.48 ±0.98
– Low grade (A0-A1) (n = 39) 25.77 ±13.06a,b 0.77 ±0.43b 0.77 ±0.43b
– High grade (A2-A3) (n = 30) 16.27 ±8.73a 2.40 ±0.68 2.40 ±0.68
– F0 (n = 24) 21.25 ±7.84a 0.0 ±0.0 0.63 ±0.49
– Low stage (F1-F2) (n = 21) 28.24 ±16.12a,c,e 0.86 ±0.36e 1.14 ±0.36d,e
– High stage (F3-F4) (n = 24) 16.5 ±7.41a,c 2.63 ±0.49 2.63 ±0.49d
*Percentage of positive cells/group, #semi-quantitative scoring of positive cells/group, A – necroinflammatory activity, F – stage of fibrosis, 
ap < 0.01 vs. control, bp < 0.01 vs. high grade, cp < 0.05, dp < 0.01 vs. F0 respectively, ep < 0.01 vs. high stage
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are known to contribute to the changes that take
place in the sinusoidal structures during the early
stage of hepatic fibrogenesis. The fibrillary
extracellular matrix build-up in the space of Disse
has been blamed for disrupting the circulation
between hepatocytes and blood [20-22]. 
Although α-SMA positivity in a few stellate cells
of the liver is normal, α-SMA expression is sig  -
nificantly increased in chronic hepatitis due to
stellate cell activation. In other studies, stellate cell
transcription has been claimed to be controlled by
α-SMA [23-26]. In the present study, significant
numbers of α-SMA-positive HSCs were detected
throughout the examined liver sections in patients
with chronic HCV infection, whereas in normal
controls α-SMA-positive cells were poorly detected.
A B
C D
Figure 2. A – Control liver section showing almost GFAP-negative perisinusoidal HSCs. B – Increased pericentral and
perisinusoidal GFAP-positive HSCs in a case of mixed lesion of CHC and schistosomiasis. C – Many perisinusoidal
GFAP-positive HSCs within the hepatic parenchyma of a liver section from a patient with CHC of low grade activity
with no evidence of fibrosis (A1F0). D – Pericentral and perisinusoidal GFAP-positive HSCs in a case of low METAVIR
score CHC (A1F1) (immunohistochemistry ×400)
GFAP – glial fibrillary acidic protein, HSCs – hepatic stellate cells, CHC – chronic hepatitis C 
Groups Perisinusoidal*, mean ± SD Periportal#, mean ± SD Pericentral#, mean ± SD
Control (n = 10) 2.3 ±1.89 0 0
Pure chronic hepatitis C (n = 34) 14.5 ±3.69a 0.70 ±1.06 0.90 ±0.99
Liver cirrhosis (n = 24) 9.83 ±5.01a 2.13 ±0.95b 1.88 ±0.95b
Mixed CHC/schistosomiasis (n = 11) 20.46 ±15.57a,c 2.36 ±0.81b 2.36 ±0.81b
Table IV. Immunoexpression of GFAP on HSCs in the studied groups
*Percentage of positive cells/group, #semi-quantitative scoring of positive cells/group, ap < 0.01 vs. control, bp < 0.01 vs. pure CHC (chronic 
hepatitis C), cp < 0.05 vs. liver cirrhosis
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In contrast, their prevalence was not associated
with the severity of fibrosis. These results are quite
consistent with those obtained by Martinelli et al.
and Carotti et al. [17, 26]. Because α-SMA is
a specific marker for smooth muscle cell dif  -
ferentiation [27], it has been used to identify
activated HSCs that show a myofibroblastic
phenotype [28, 29]. However, the association
between the α-SMA-positive HSCs and the extent
of fibrosis is controversial. A lack of correlation
between the prevalence of α-SMA-positive HSCs
and fibrosis severity in chronic liver disease was
reported by Levy et al. [30], whereas a positive
correlation has been found in other studies [10, 26,
31]. The precise subpopulation of α-SMA-positive
HSCs/myofibroblasts related to fibrosis is still
debated [32, 33]. 
The presence of α-SMA-positive HSCs in stage 0
fibrosis CHC disease suggested that HSCs were
already activated by the virus infection, even in the
absence of detectable fibrosis. These cells may
return to an inactive state once fibrosis is well
established, especially in the absence of ongoing
hepatic inflammation. In the present study, the
mean value of perisinusoidal HSCs positive for 
α-SMA in CHC cases with stage 0 fibrosis was 21.25
±7.84 and in advanced stage 3-4 fibrosis was 16.5
±7.41, which were closely related and distinct from
those in stage 1-2 fibrosis: 28.24 ±16.12. In CHC,
both Th1 and Th2 subsets of lymphocytes are
important in regulating host responses via cytokine
production [34, 35]. In general, Th1 cells produce
cytokines such as interferon-γ and tumour necrosis
factor that promote inflammation and cell-
mediated immunity in an attempt to control
infection. Th2 lymphocytes produce cytokines,
especially interleukin 4, that favour fibrogenesis in
liver injury to a greater extent than Th1 lymphocytes
[36-38]. The increased abundance of IL-4 message
identified in stage 1-2 fibrosis is therefore likely to
contribute to the overall fibrogenic process. The
characterization of a more specific marker for
activated HSCs could be helpful in improving the
predictive role of HSC detection.
Table V. GFAP immunoexpression on HSCs in controls as well as HCV patients with different grades and stages
Groups Perisinusoidal*, mean ± SD Periportal#, mean ± SD Pericentral#, mean ± SD
Control (n = 10)  2.3 ±1.89 0 0
Chronic hepatitis C (n = 69) 16.10 ±8.38a 1.09 ±1.19 1.17 ±1.01
– Low grade (A0-A1) (n = 39) 21.21 ±6.91a,b 0.46 ±0.94b 0.77 ±0.9b
– High grade (A2-A3) (n = 30) 9.47 ±4.64a 1.9 ±0.96 1.7 ±0.92
– F0 (n = 24) 24.38 ±5.77a 0.13 ±0.34 0.38 ±0.49
– Low stage (F1-F2) (n = 21) 13.81 ±6.26a,c,d 1.0 ±1.1c,e 1.29 ±0.9c,d
– High stage (F3-F4) (n = 24) 9.83 ±5.01a,c 2.13 ±0.95c 1.88 ±0.95c
*Percentage of positive cells/group, #semi-quantitative scoring of positive cells/group, A – necroinflammatory activity, F – stage of fibrosis, 
ap < 0.01 vs. control, bp < 0.01 vs. high grade, cp < 0.01 vs. F0, dp < 0.05, ep < 0.01 vs. high stage
25
20
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Figure  3.  Expression of α-SMA and GFAP on
perisinusoidal HSCs among all studied groups 
(**p < 0.01 vs. GFAP)
α-SMA – α-smooth muscle actin, GFAP – glial fibrillary acidic
protein, CHC – chronic hepatitis C, LC – liver cirrhosis, HSCs
– hepatic stellate cells, 
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Figure 4. Correlation between expression of α-SMA
and GFAP on HSCs in the studied HCV-infected
patients (r = 0.313, p < 0.01)
α-SMA – α-smooth muscle actin, GFAP – glial fibrillary acidic
protein, HSCs – hepatic stellate cells, HCV – hepatitis C virus
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Glial fibrillary acidic protein is an intermediate
filament first identified and characterized in
astroglial cells [39]. Hepatic stellate cells share
several features with astrocytes of the central
nervous system, such as juxtaposition to the
capillaries, a stellate shaped appearance [40], and
response to tissue injuries [41].
The role of GFAP expression in HSCs is currently
unknown. Previous studies in rodents showed that
HSCs contained an unusually broad spectrum of
intermediate filament proteins [42, 43]. The
accumulation of GFAP/desmin-positive HSCs in an
early stage of fibrosis [44], the proliferation of cells
[45], and the expression of extracellular matrix
genes and proteins [46, 47], which are hallmarks of
activated HSCs, suggested that an increased
expression level of GFAP by HSCs could be related
to their initial activation changes.
Reports concerning GFAP expression in human
liver are conflicting. A rim of GFAP-positive cells
around portal tracts in normal liver and increased
staining in the cirrhotic nodule without staining in
the fibrous septa have been described [48]. In
another study [49], GFAP was not detected in
normal liver HSCs but was detected in focal
periportal areas in cirrhotic liver. Few studies have
been performed in order to quantify the hepatic
expression of GFAP at different stages of human
chronic hepatitis [12]. In the present study, GFAP-
expressing HSCs seem to be related to early phases
of fibrotic tissue deposition. We found that the
percentage of perisinusoidal GFAP-positive HSCs
was lowest in the cirrhotic patients compared to
those with lower stages of fibrosis, especially 
stage 0 fibrosis; this means that the extent of GFAP
expression correlates negatively with the stage of
fibrosis. This might have a great impact on selection
of patients for antiviral treatment. Currently,
patients with low grade necroinflammation and
stage 0 fibrosis are not treated but are followed up
with the risk of decreased response to treatment if
fibrosis later ensues. In view of our results, those
patients can be candidates for treatment if the
follow-up liver biopsy showed an appreciable
decrease in the expression of GFAP on HSCs even
without aberrant histopathological changes in
grading or staging.
In the present study, we observed a remarkably
higher number of α-SMA and GFAP-positive cells in
patients with mixed CHC/schistosomiasis compared
with the normal controls. Moreover, we found
a significant predominance of GFAP-positive HSCs
in relation to α-SMA-positive ones, suggesting that
HSCs and not liver myofibroblasts may be the main
cellular source of connective extracellular matrix
deposited in portal spaces of schistosomiasis. These
data agree with Chang et al. [13] and the experi  -
mental studies which found that activated Ito cells
participate in the deposition of extracellular matrix
in periovular schistosomal granulomas [50, 51].
In this study, α-SMA expression correlated
significantly with the expression of GFAP in chronic
HCV-infected patients. Carotti et al. [17] found that
α-SMA and GFAP immunoreactivity partially
overlapped, some HSCs being α-SMA-positive and
GFAP-positive; others are stained either for α-SMA
or GFAP . 
In conclusion, GFAP could represent a useful
marker of early activation of HSCs in chronic HCV
disease. GFAP and α-SMA dependent activation of
HSCs precedes fibrotic tissue deposition, inversely
correlating with fibrosis and necroinflammatory
activity. This might have a great impact on selection
of patients for antiviral treatment. The GFAP-
positive cells could be the precursors of fully
activated HSCs identified by α-SMA immuno  -
reactivity, or they could represent a subpopulation
of different origin. Further studies are needed to
investigate the origin of GFAP-positive HSCs in
human liver.
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